PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22047130-9	2011	RESULTS: Diazoxide inhibited in vitro nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) production and inducible nitric oxide synthase (iNOS) expression by activated microglia without affecting cyclooxygenase-2 (COX-2) expression and phagocytosis.	Diazoxide	9-18	tumor necrosis factor	Mus musculus	57-84	
22047130-9	2011	RESULTS: Diazoxide inhibited in vitro nitric oxide (NO), tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) production and inducible nitric oxide synthase (iNOS) expression by activated microglia without affecting cyclooxygenase-2 (COX-2) expression and phagocytosis.	Diazoxide	9-18	tumor necrosis factor	Mus musculus	86-95	
16257489-4	2006	K(ATP) channel openers (KCOs) including pinacidil, diazoxide and iptakalim (Ipt) exerted beneficial effects on rotenone-induced morphological alterations of BV-2 cells, decreased tumor necrosis factor alpha (TNF-alpha) production and the expression and activity of inducible isoform of nitric oxide synthase (iNOS).	Diazoxide	51-60	tumor necrosis factor	Mus musculus	179-206	
15153522-5	2004	Diazoxide that attenuates voltage-activated Ca(2+) currents inhibited MIN6N8 cell death by IFN-gamma/TNF-alpha, while glibenclamide that accentuates voltage-activated Ca(2+) currents augmented insulinoma cell death.	Diazoxide	0-9	tumor necrosis factor	Mus musculus	101-110	
12160952-10	2002	Interestingly, pharmacologic preconditioning with adenosine (100 microM) and diazoxide (30 microM) mimicked IP in both the wild-type (infarct size-11+/-4% and 18+/-2%) and in TNFalpha-/- mice (infarct size-15+/-4% and 23+/-3%) versus respective I/R controls.	Diazoxide	77-86	tumor necrosis factor	Mus musculus	175-183